Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Summary

This 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with 154 respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers.

The report includes -
- Study Design and Key Findings.
- Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
- Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
- Challenges Facing Decentralized Trials, which explores the biggest challenges, changes, considerations and risk deviations for decentralized clinical trials.

Scope

- A total of 154 GlobalData Pharma clients and prospects from the around the world participated in the seven-minute survey, which was fielded from August 3, 2021 to September 2, 2021.
- This report includes and is based around industry opinions on COVID-19s impact on clinical trials and the use of decentralized clinical trials.

Reasons to Buy

- Understand companies primary concerns about the COVID-19 pandemic.
- Determine the impact of COVID-19 to date on clinical trials.
- Assess companies future plans to use decentralized clinical trials.
- Track changes to clinical trial strategy and attitudes.

1 Study Design
1.1 Background
1.2 Objectives and Design
1.3 Respondent Mix
1.4 Respondent Profiles
2 Key Findings
3 Primary Business and Clinical Trial Concerns
3.1 Primary Business Concerns
3.2 Primary Clinical Trial Concerns
3.3 Clinical Trial Disruptions
3.4 Addressing Clinical Trial Disruptions
4 Movement Toward Decentralized Trials
3.1 Pre-pandemic Decentralized Trials Use
3.2 Post-pandemic Decentralized Trials Use
3.3 Future Movement Toward Decentralized Clinical Trial Use
3.4 Cost Comparison
4 Challenges Facing Decentralized Trials
4.1 Biggest Challenges
4.2 Biggest Changes
4.3 Biggest Considerations
4.4 Risk Deviations
5 Summary
6 Appendix

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is

USD 1495 View Report

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the

USD 2495 View Report

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the

USD 2495 View Report

Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021

Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021GlobalDatas clinical trial report, Coronavirus Disease 2019 (COVID-19) - Global Clinical Trials Review, H2, 2021 provides an overview of Coronavirus

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available